MedTrace Logo

A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma

NCT07589257 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-05-15

No results posted yet for this study

Summary

To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG

Conditions

  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Diffuse Intrinsic Pontine Glioma

Interventions

DRUG

VRT106 for injection

VRT106, iv

Sponsors & Collaborators

  • Guangzhou Virotech Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuanyuan Chen · Sun Yat-Sen University Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-07
Primary Completion
2028-06-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07589257 on ClinicalTrials.gov